An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
NCT05025241
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Phelan-McDermid Syndrome
Interventions
DRUG:
NNZ-2591
Sponsor
Neuren Pharmaceuticals Limited